Skip to main content
Premium Trial:

Request an Annual Quote

Wistar Institute, Graham Cancer Center Partner for Gene Editing in Cancer Research

NEW YORK (GenomeWeb) – The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute have announced a partnership for gene editing in cancer research.

Under the terms of the partnership, Graham's Gene Editing Institute will be integrated into Wistar's Molecular Screening Facility, though it will keep its management structure and will continue to be located on the Christiana Hospital Campus in Newark, Delaware.

Financial and other terms of the agreement were not disclosed.

"Bringing together scientists from the Gene Editing Institute and Wistar promises to be a catalyst that will speed progress in personalized medicine for cancer and other diseases," Graham Cancer Center Medical Director Nicholas Petrelli said in a statement. The Gene Editing Institute brings experience with CRISPR and transcription activator-like effector nucleases (TALENs).

Eric Kmiec of the Gene Editing Institute added that the organization have already begun collaborating on melanoma and lung cancer research.

The deal extends the relationship between Wistar and the Graham Cancer Center, started in 2011. As part of that relationship, the organizations collaborated on a lung cancer diagnostic test in 2012.